Aastrom Biosciences Added to Russell Microcap Index
June 30 2014 - 8:30AM
Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of
patient-specific expanded cellular therapies for the treatment of
severe diseases and conditions, today announced that it will be
included in the Russell Microcap® Index, according to information
posted by Russell Investments on June 27, 2014. The final
membership lists will be posted on June 30, 2014, with trading in
the reconstituted indexes commencing that same day.
According to Russell, annual reconstitution of Russell Indexes
captures the 4,000 largest U.S. stocks as of the end of May,
ranking them by total market capitalization to create the Russell
3000® Index and Russell Microcap® Index. Inclusion in the Russell
Microcap® Index will remain in place for the ensuing 12-month
period. The Russell Indexes are widely used by investment managers
and institutional investors for index funds and as benchmarks for
active investment strategies. Approximately $5.2 trillion in assets
currently are benchmarked to Russell Indexes.
"This has been a transformational year for Aastrom given our
recent acquisition of Sanofi's cell therapy and regenerative
medicine business and the initiation of commercial sales of bone
marrow by Marrow Donation LLC, our wholly-owned bone marrow
collection center," said Nick Colangelo, president and CEO of
Aastrom. "We are very pleased to be added to the Russell Microcap
Index and look forward to sharing additional news about important
developments at Aastrom this year with the investment
community."
About the Russell Microcap Index
The Russell Microcap® Index measures the performance of the
microcap segment of the U.S. equity market. Microcap stocks make up
less than 3% of the U.S. equity market (by market cap) and consist
of the smallest 1,000 securities in the small-cap Russell 2000®
Index, plus the next 1,000 smallest eligible securities by market
cap. The Russell Microcap Index is constructed to provide a
comprehensive and unbiased barometer for the microcap segment
trading on national exchanges. The Index is completely
reconstituted annually to ensure new and growing equities are
reflected and companies continue to reflect appropriate
capitalization and value characteristics.
About Aastrom Biosciences
Aastrom Biosciences is the leader in developing patient-specific
expanded cellular therapies for use in the treatment of patients
with severe diseases and conditions. Aastrom markets two autologous
cell therapy products in the United States for the treatment of
cartilage repair and skin replacement. Aastrom is also developing
MACI, a third generation autologous chondrocyte implant for the
treatment of cartilage defects in the knee, and ixmyelocel-T, a
patient-specific multicellular therapy for the treatment of
advanced heart failure due to ischemic dilated cardiomyopathy. For
more information, please visit Aastrom's website at
www.aastrom.com.
The Aastrom Biosciences, Inc. logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=3663
This document contains forward-looking statements, including,
without limitation, statements concerning the anticipated market
for bone marrow and bone marrow-derived cells, and objectives and
expectations regarding the business opportunity described herein
and the Company's recent acquisition, all of which involve certain
risks and uncertainties. These statements are often, but are not
always, made through the use of words or phrases such as
"anticipates," "intends," "estimates," "plans," "expects," "we
believe," "we intend," and similar words or phrases, or future or
conditional verbs such as "will," "would," "should," "potential,"
"could," "may," or similar expressions. Actual results may differ
significantly from the expectations contained in the
forward-looking statements. Among the factors that may result in
differences are the inherent risks and uncertainties associated
with competitive developments, product development activities, the
availability and allocation of resources among different potential
uses, market demand for bone marrow and bone marrow-derived cells
for research purposes, and our ability to supply or meet customer
demand for bone marrow and bone-marrow derived cells. These and
other significant factors are discussed in greater detail in
Aastrom's Annual Report on Form 10-K for the year ended December
31, 2013, filed with the Securities and Exchange Commission ("SEC")
on March 13, 2014, Quarterly Reports on Form 10-Q and other filings
with the SEC. These forward-looking statements reflect management's
current views and Aastrom does not undertake to update any of these
forward-looking statements to reflect a change in its views or
events or circumstances that occur after the date of this release
except as required by law.
CONTACT: Media contact:
David Salisbury
Berry & Company
dsalisbury@berrypr.com
(212) 253-8881
Investor contact:
Chad Rubin
The Trout Group
crubin@troutgroup.com
(646) 378-2947
Vericel (NASDAQ:VCEL)
Historical Stock Chart
From Apr 2024 to May 2024
Vericel (NASDAQ:VCEL)
Historical Stock Chart
From May 2023 to May 2024